Seroconversion for Hepatitis C Virus Antibody in Bone Marrow Recipients Treated with Immune Globulin

Publisher Website
Google Scholar
Abstract
Sullivan and colleagues (Sept. 13 issue)1 reported that patients receiving intravenous polyvalent immune globulin after bone marrow transplantation had a significantly reduced risk of septicemia, local infection, interstitial pneumonia, and acute graft-versus-host disease (GVHD). Intravenous immune globulin is also given to patients who undergo grafting at our institution; immune globulin (Gammagard, Baxter) is administered at a dose of 200 mg per kilogram of body weight every other week for six months, starting on the day before bone marrow infusion.